Target offers extra deals through Cartwheel for holiday shopping season
MINNEAPOLIS — Target will make use of its omnichannel offerings for Black Friday, the mass-merchandise retailer said Monday.
Target, whose stores will open on Thanksgiving day at 8 p.m., will offer sales in stores and on its website, as well as through the Cartwheel mobile app.
"For both our guests and team members, Black Friday is an exciting event that officially marks the beginning of the holiday shopping season," Target EVP Merchandising and Supply Chain said. "By offering advance access to deals at Target.com and opening our stores earlier, we are making it easier for guests to build a Black Friday ritual that works for them."
Cartwheel will feature deals throughout Thanksgiving week, and customers who redeem any offer through the app will also unlock an additional offer card, enabling them to select a deal of their choice. In addition, the chain is offering an additional 5% savings on almost all purchases made using the REDcard, Target’s loyalty card program.
Patient Views – November 2013 Methodology
AccentHealth collected data through an online survey conducted from Oct. 14 to 21. Participants responded via AccentHealth’s national, online panel of network viewers, and the survey yielded 520 respondents who were at least 18 years of age, and either themselves or a household member have prediabetes, Type 1 diabetes or Type 2 diabetes.
All data is self-reported and not validated.
Below is the demographic breakdown of the respondents and their behavior:
Primary shopper in household
Novartis to sell off blood transfusion diagnostics unit
BASEL, Switzerland — Swiss drug maker Novartis is selling its blood transfusion diagnostics business to a Spanish manufacturer for $1.675 billion, Novartis said Monday.
The drug maker said it expected the sale, to Grifols, to be completed in 2014. Novartis bought the Emeryville, Calif.-based unit in 2006 as part of its acquisition of Chiron. Its sales in 2012 were about $565 million. Grifols is headquartered in Barcelona.
"The sale of the Novartis blood transfusion diagnostics unit enables us to focus more sharply on our strategic businesses while providing Grifols with a platform for global expansion," Novartis CEO Joseph Jimenez said. "I am especially pleased that the agreement with Grifols provides our associates with an opportunity to join a company that will focus on growing this business aggressively."